TABLE 1.
Saccharomyces cerevisiae strains used in this study
| Straina | Genotype or description | Source |
|---|---|---|
| AD1-8u- | MATα, PDR1-3, ura3, his1, Δyor1::hisG, Δsnq2::hisG, Δpdr10::hisG, Δpdr11::hisG, Δycf1::hisG, Δpdr3::hisG, Δpdr15::hisG, Δpdr5::hisG | 34 |
| AD/pABC3 | AD1-8u-, Δpdr5::pABC3 (empty vector control) | 20 |
| AD/CDR1 | AD1-8u-, Δpdr5::pABC3-CDR1B | 20 |
| AD/CDR1-G521R | Milbemycin α25-resistant isolate R25-2 | This study |
| AD/CDR1-G521R | Enniatin B-resistant isolate EN-1 | This study |
| AD/CDR1-G521V | Enniatin B-resistant isolate EN-2 | This study |
| AD/CDR1-G521S | Beauvericin-resistant isolate BE-1 | This study |
| AD/CDR1-G521C | Beauvericin-resistant isolate BE-2 | This study |
| AD/CDR1-G521V | Beauvericin-resistant isolate BE-3 | This study |
| AD/CDR1-M639I | Milbemycin α25-resistant isolate R25-3 | This study |
| AD/CDR1-M639I | Milbemycin α25-resistant isolate R25-8 | This study |
| AD/CDR1-M639I | Milbemycin α25-resistant isolate R25-9 | This study |
| AD/CDR1-M639I | Enniatin B-resistant isolate EN-3 | This study |
| AD/CDR1-L664I | Enniatin B-resistant isolate EN-4 | This study |
| AD/CDR1-L665S | Enniatin B-resistant isolate EN-5 | This study |
| AD/CDR1-V668I | Enniatin B-resistant isolate EN-6 | This study |
| AD/CDR1-V668D | Beauvericin-resistant isolate BE-4 | This study |
| AD/CDR1-A713P | Milbemycin α25-resistant isolate R25-1 | This study |
| AD/CDR1-A713P | Milbemycin α25-resistant isolate R25-6 | This study |
| AD/CDR1-A713P | Milbemycin α25-resistant isolate R25-7 | This study |
| AD/CDR1-F1235V | Enniatin B-resistant isolate EN-7 | This study |
| AD/CDR1-T1355N | Milbemycin α25–resistant isolate R25-5 | This study |
| AD/CDR1-M1356I | Enniatin B-resistant isolate EN-8 | This study |
a
Mutant strains are listed in order according to where in the molecule their CDR1 mutations occurred and in which inhibitor-resistance screen they were isolated.